Trial reportBMC medicine2020
Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.
Trial report in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Understanding the research landscape of over-the-counter herbal products, dietary supplements, and medications evaluated for depressive symptoms in adults: a scoping review.Frontiers in pharmacology · 2025Pooled it
- Genome-wide association study implicates the role of TBXAS1 in the pathogenesis of depressive symptoms among the Korean population.Translational psychiatry · 2024Pooled it
- Inflammation and depression in young people: a systematic review and proposed inflammatory pathways.Molecular psychiatry · 2022Pooled it
- Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies.Frontiers in psychiatry · 2021Pooled it
- Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.PloS one · 2021Pooled it
- No Effect of Low-Dose Aspirin Versus Placebo as Add-On Treatment in Bipolar Disorder-Results From a Randomised Controlled Trial (the A-Bipolar RCT).Acta psychiatrica Scandinavica · 2026Trial
- Aspirin and atorvastatin augmentation treatment in patients with major affective disorders and inflammatory dysregulation: a 12-week randomised Placebo-controlled study.Acta neuropsychiatrica · 2026Trial
- Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study.Psychopharmacology · 2022Trial
- An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers.Psychopharmacology · 2022Trial
- The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study.Journal of psychopharmacology (Oxford, England) · 2021Trial
- Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.Molecular psychiatry · 2021Trial
- An international, double-blind, randomized, placebo-controlled clinical trial of adjunctive trimetazidine to treat people with bipolar depression (the TIDE trial) protocol.BMC psychiatry · 2026Article
- Aspirin use and risk of depression: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Article
- Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.International journal of molecular sciences · 2025Review
- Neuroinflammation-A Crucial Factor in the Pathophysiology of Depression-A Comprehensive Review.Biomolecules · 2025Review
- Graded changes in local functional connectivity of the cerebral cortex in young people with depression.Psychological medicine · 2025Article
- A Bibliometric Analysis of Neuroinflammation in Depression from 2004 to 2023: Global Research Hotspots and Prospects.International journal of medical sciences · 2025Review
- Immuno-metabolic depression: from concept to implementation.The Lancet regional health. Europe · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundInflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvastatin, compared with placebo, reduced depressive symptoms in young people (15-25 years).
methodsYoDA-A, Youth Depression Alleviation with Anti-inflammatory Agents, was a 12-week triple-blind, randomised, controlled trial. Participants were young people (aged 15-25 years) with moderate to severe MDD (MADRS mean at baseline 32.5 ± 6.0; N = 130; age 20.2 ± 2.6; 60% female), recruited between June 2013 and June 2017 across six sites in Victoria, Australia. In addition to treatment as usual, participants were randomised to receive aspirin (n = 40), rosuvastatin (n = 48), or placebo (n = 42), with assessments at baseline and weeks 4, 8, 12, and 26. The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to week 12.
resultsAt the a priori primary endpoint of MADRS differential change from baseline at week 12, there was no significant difference between aspirin and placebo (1.9, 95% CI (- 2.8, 6.6), p = 0.433), or rosuvastatin and placebo (- 4.2, 95% CI (- 9.1, 0.6), p = 0.089). For rosuvastatin, secondary outcomes on self-rated depression and global impression, quality of life, functioning, and mania were not significantly different from placebo. Aspirin was inferior to placebo on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) at week 12. Statins were superior to aspirin on the MADRS, the Clinical Global Impressions Severity Scale (CGI-S), and the Negative Problem Orientation Questionnaire scale (NPOQ) at week 12.
conclusionsThe addition of either aspirin or rosuvastatin did not to confer any beneficial effect over and above routine treatment for depression in young people. Exploratory comparisons of secondary outcomes provide limited support for a potential therapeutic role for adjunctive rosuvastatin, but not for aspirin, in youth depression.
trial registrationAustralian New Zealand Clinical Trials Registry, ACTRN12613000112763. Registered on 30/01/2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.